Us-Israeli pharmaceutical company Kite Pharma published the results of a phase I clinical study of its drug KTE-C19 CAR, intended for treating aggressive forms of non-Hodgkin’s lymphoma.
According to these figures, four of the seven study participants was complete and one partial remission.
The company plans to start phase II clinical studies in 2016, after receiving additional results from the first phase.
It should be noted that Kite Pharma are developing a drug-based targeted immunotherapy, has received from American Federal Agency on control of drugs and food (FDA) status of a fundamentally new medicines to expedite the approval process before entering the market.
The company Kite Pharma based Israeli scientist Arieh Belldegrun in 2009. Belldegrun, among other things, is a member of the Board of Directors of the pharmaceutical company «Teva».
The next day after publication of the results of the first phase of the study Kite Pharma had filed the stock exchange of high technologies NASDAQ a plan to mobilize $ 250 million. The value of the company, have still not earned a cent, is estimated at 3.3 billion dollars.